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London, UPurpose: In men with localized prostate cancer, dose-escalated conformal radiotherapy (CFRT) improves efficacy
outcomes at the cost of increased toxicity. We present a detailed analysis to provide further information about the
incidence and prevalence of late gastrointestinal side effects.
Methods and Materials: The UKMedical Research Council RT01 trial included 843menwith localized prostate can-
cer, who were treated for 6months with neoadjuvant radiotherapy andwere randomly assigned to either 64-Gy or 74-
Gy CFRT. Toxicity was evaluated before CFRT and during long-term follow-up using Radiation Therapy Oncology
Group (RTOG) grading, the Late Effects on Normal Tissue: Subjective, Objective, Management (LENT/SOM) scale,
and RoyalMarsdenHospital assessment scores. Patients regularly completed Functional Assessment of Cancer Ther-
apy–Prostate (FACT-P) andUniversity ofCalifornia, LosAngeles, ProstateCancer Index (UCLA-PCI) questionnaires.
Results: In the dose-escalated group, the hazard ratio (HR) for rectal bleeding (LENT/SOM grade $2) was 1.55
(95%CI, 1.17–2.04); for diarrhea (LENT/SOM grade$2), the HR was 1.79 (95% CI, 1.10–2.94); and for proctitis
(RTOG grade$2), the HRwas 1.64 (95%CI, 1.20–2.25). Compared to baseline scores, the prevalence of moderate
and severe toxicities generally increased up to 3 years and than lessened. At 5 years, the cumulative incidence of
patient-reported severe bowel problems was 6% vs. 8% (standard vs. escalated, respectively) and severe distress
was 4% vs. 5%, respectively.
Conclusions: There is a statistically significant increased risk of various adverse gastrointestinal events with dose-
escalated CFRT. This remains at clinically acceptable levels, and overall prevalence ultimately decreases with
duration of follow-up.  2010 Elsevier Inc.
Prostate cancer, Conformal radiotherapy, Dose escalation, Late gastrointestinal toxicity, Phase III trial.
Open access under CC BY license.INTRODUCTION
Patients with low or intermediate risk prostate cancer have
improved disease outcome in terms of local control, bio-
chemical control, and disease-free survival if they are
treated with dose-escalated rather than ‘‘standard-dose’’
conformal radiotherapy (CFRT) according to five random-
ized controlled trials from North America, The Netherlands,
and the UK. However, dose-escalated radiotherapy has
more late gastrointestinal effects and not bladder toxicity
(1–7). Long-term survival after treatment is the rule (9);
thus, patients who develop significant side effects fromt requests to: Matthew R.Sydes, MRC Clinical Trials Unit,
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773radical radiotherapy may have to live with them for a pro-
longed period of time.
The Medical Research Council (MRC) RT01 trial was
a large, multicenter, randomized controlled trial in men
with localized prostate cancer, who were randomized to re-
ceive either standard (64-Gy) or dose-escalated (74-Gy)
CFRT. All patients received neoadjuvant hormone therapy.
The design, patient, and treatment data and toxicity and early
outcome results (6–8) have been presented in detail: at 5
years, the cumulative incidence for RTOG grade $2 bowel
toxicity was 24% for the standard-dose group and 33% forSupplementary material for this article can be found at www.
redjournal.org.
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Table 1. Cumulative incidence and risk of rectal bleeding
Cumulative incidence at 5 years
64 Gy 74 Gy
Symptom: scale HR 95% CI n patients % of patients n patients % of patients
Rectal bleeding: RMH
Mild 1.32 1.08–1.61 170 43 111 53
Moderate 1.97 1.37–2.84 43 11 81 21
Severe 1.65 0.39–6.92 3 1 5 1
Objective bleeding: LENT/SOM
Grade $2 1.55 1.17–2.04 83 22 121 32
Grade $3 3.12 1.63–6.01 12 3 36 10
Grade $4 0.68 0.11–4.04 3 1 1 1
Management bleeding: LENT/SOM
Grade $2 1.54 0.74–3.20 9 3 17 4
Grade $3 3.07 0.83–11.33 3 1 8 2
Grade $4 5.12 0.60–43.8 1 0 4 1
774 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 3, 2010the escalated-dose group (6–8). We report here the detailed
analysis of late bowel toxicity.
METHODS AND MATERIALS
The MRC RT01 trial recruited men with T1b to T3a, N0, M0 pros-
tate cancer, with a prostate-specific antigen concentration of#50 ng/ # pts returning all forms:
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Fig. 1. Prevalence and cumulative incidence of rectal bleeding.
standard arm, 64 Gy; Esc = escalated arm, 74 Gy; m = month; g
diation therapy.ml. Patients received androgen suppression for 3 to 6 months before
radiotherapy started. Patients were randomized to receive either 64
Gy in 32 fractions (standard group) or 74 Gy in 37 fractions (escalated
group) (6, 7). The dose to rectum, small bowel, and anal canal was not
routinely calculated during the planning process, and no attempt was
made to reduce normal tissue doses. Patients were assessed for toxic-
ities before starting androgen suppression, before starting Number at risk: OVERALL SURVIVAL
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(A, B) RMH; (C, D) LENT/SOM. Obj = objective; Std =
r = grade; pre-H = prehormonal therapy; pre-RT = prera-
Table 2. Cumulative incidence and risk of diarrhea and frequency
Cumulative incidence at 5 years
64 Gy 74 Gy
Symptom: scale HR 95% CI n patients % of patients n patients % of patients
Diarrhea: RTOG
Grade $1 1.06 0.84-1.34 130 33 137 34
Grade $2 1.59 1.07-2.35 38 10 60 15
Grade $3 3.04 1.21-7.67 5 1 16 4
Bowel frequency: RMH
Mild 1.12 0.89-1.41 139 32 144 36
Moderate 1.38 0.92-2.07 35 9 54 14
Severe 2.23 1.09-4.55 9 2 24 6
Subjective stool frequency: LENT/SOM
Grade $1 1.07 0.87-1.32 172 44 181 46
Grade $2 1.79 1.10-2.94 23 6 43 12
Grade $3 NA NA 0 0 9 2
Management tenesmus: LENT/SOM
Grade $2 1.42 0.83-2.42 6 23 8 32
Grade $3 2.28 0.70-7.41 1 4 2 9
Grade $4 NA NA 0 0 0 0
Loose stools: UCLA-PCI
Mild 1.14 0.98-1.31 360 91 378 94
Moderate 1.25 0.90-1.73 66 17 77 21
Severe 0.95 0.51-1.75 21 6 20 6
Pain abdomen: UCLA-PCI
Mild 1.19 0.98-1.44 193 51 223 58
Moderate 1.53 1.13-2.06 71 21 103 28
Severe 1.55 0.84-2.86 17 5 26 7
Abbreviation: NA = not applicable.
Late bowel toxicity of prostate CFRT d I. SYNDIKUS et al. 775radiotherapy, and at 6, 12, 18, and 24 months and annually thereafter.
Only events reported at least 6 months after starting radiotherapy were
deemed late events. Events occurring earlier were considered early
toxicities, and descriptions have been published previously (6).Toxicity assessment
Three physician-completed toxicity assessments were used: the Ra-
diation Therapy Oncology Group (RTOG) (10) scale, the Royal Mars-
den Hospital (RMH) scale (5), and the Late Effects on Normal Tissue,
Subjective, Objective, Management (LENT/SOM) questionnaire (11).
The RTOG scale used matched that from the pilot study, measuring
five bowel toxicities separately (10). It was not completed at preradio-
therapy assessments. The RMH scale consists of five questions assess-
ing the commonest bowel side effects after pelvic radiotherapy. The
LENT/SOM instrument divides toxicity into subjective symptoms
reported by patients (e.g., pain), objective symptoms (e.g., diarrhea),
and medical intervention required to control toxicity (e.g.,medications
or transfusions). Additionally, patients completed UCLA Prostate
Cancer Index (UCLA-PCI) (12) and Functional Assessment of Cancer
Therapy-Prostate (FACT-P) (13) scales to assess quality of life. These
questionnaires asked 27 questions about bowel symptoms.
Responses to RTOG questions were categorized as grades 0, 1, 2,
and $3 for this analysis. LENT/SOM grades 0 to 1 were broadly
equivalent to RTOG grade 0; therefore, LENT/SOM grades 2, 3,
and 4 translated to RTOG grades 1, 2, and $3. However, LENT/
SOM diarrhea grade 1 was similar to RTOG grade 1 severity, and
so it was categorized as 0, 1, 2, and$3 (see Table E1 in the supple-
mentary material). The RMH, UCLA-PCI, and FACT-P questions
did not have standard combined scales, so each variable from these
questionnaires was considered individually, with response cate-
gories designated mild, moderate, or severe (see Table E1 in the sup-plementary material). The composite RTOG score has previously
been reported (7) and is not detailed additionally here.Statistical analyses
Analyses used a two-sided, 5% significance level on an intention-
to-treat basis, with randomized patients analyzed according to their
allocated treatment group. All analyses were performed using Stata
(version 9) software.
Standard time-to-event (survival analysis) methodology was used
to assess the first reported incidence of each severity level of each
toxicity endpoint. Events were timed from the start of radiotherapy,
and the differences between the treatment groups were tested using
the log-rank test. Relative risks of these unwanted effects according
to treatment are summarized using hazard ratios (HR) with 95%
confidence intervals (CI) from Cox regression models. All compar-
isons are expressed relative to the standard group; so an HR value of
<1.00 indicates lower risk of toxicity in the escalated-dose group.
The prevalence of each grade of toxicity at each time point (including
pretreatment) is presented in tables and as stacked bar graphs; no formal
statistical tests have been performed with these data. These graphs pres-
ent all data collected between 10% below and 30% above a certain time
point in days, to a maximum of 6 months. Only patients for whom all
five assessments were available for a certain time point were included in
these analyses. Data for these analyses were frozen in March 2007;
thus, this work is based on the same dataset as the efficacy results paper,
which contained an overview of toxicity results (7).RESULTS
Between January 1998 and December 2001, 843 men were
randomized to MRC RT01: 422 men were allocated to the
 # pts returning all forms:
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Fig. 2. Prevalence and cumulative incidence of diarrhea. (A, B) RTOG; (C, D) RMH; (E, F) LENT/SOM; (G, H) UCLA-
PCI; (I, J) abdominal pain, UCLA-PCI. Subj = subjective; Std = standard arm; Esc = escalated arm; m = month; gr = grade;
pre-H = prehormonal therapy; pre-RT = preradiation therapy.
776 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 3, 2010escalated-dose arm, and 421 men were allocated to the stan-
dard arm. Compliance with the allocated treatment was ex-
cellent, with 95% of the standard and 97% of the escalatedpatients receiving the correct radiotherapy dose. At the prera-
diotherapy time point, all five forms were returned for 702/
843 (83%) patients. Compliance with all scales at 6, 12,
# pts returning all forms:
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Fig. 2. (continued).
Late bowel toxicity of prostate CFRT d I. SYNDIKUS et al. 777and 24 months was 605/764 (79%) patients, 645/790 (82%)
patients, and 592/762 (78%) patients, respectively, and was
306/592 (52%) patients at 5 years.
Rectal bleeding
Clinicians recorded low baseline levels of rectal bleeding
for 34/702 (5%) patients having mild and 4/702 (1%) patients
having moderate bleeding on the RMH scale, and 10/702
(1%) patients having grade 2 on the LENT/SOM scale. Rec-
tal bleeding was the most commonly reported bowel toxicity,
with a cumulative incidence by 5 years for mild-or-worse
bleeding on the RMH scale at 43% (170 patients) for the stan-
dard group and 53% (211) for the escalated group (Table 1).
Escalated patients were significantly more likely to report
mild-or-worse bleeding and moderate-or-worse bleeding, ac-
cording to the RMH scale (mild-or-worse HR = 1.32; 95%
CI, 1.08-1.61; moderate-or-worse HR = 1.97; 95% CI,
1.37-2.84). They were also significantly more likely to report
grade $2 and grade $3 bleeding on the LENT/SOM objec-
tive scale (grade$2 HR = 1.55; 95% CI, 1.17-2.04; grade$3HR = 3.12; 95% CI, 1.63-6.01). Severe bleeding was rare; by
5 years from starting radiotherapy, just 3 standard and 5 esca-
lated patients reported the most severe RMH toxicity; 3 and 1
patients reported the most severe LENT/SOM toxicity. Esca-
lated patients required more medical interventions for bleed-
ing (LENT/SOM bleeding management), but the difference
was not statistically significant: by 5 years, 17 escalated pa-
tients had required $1 transfusion or laser treatment, 8 esca-
lated patients had required more regular transfusions, and 4
escalated patients required surgery compared with 9, 3, and
1 patients in the standard arm, respectively. After 6 months,
the escalated arm patients had a higher prevalence of any
bleeding toxicity at almost every time point (Fig. 1). Inci-
dence peaked around 3 years after radiotherapy, and at 5
years, levels remained higher than those at baseline in both
arms. The slowly rising overall incidence was due to new re-
ports of bleeding up to 5 years postradiotherapy. For exam-
ple, between 2 and 5 years after radiotherapy, 28
occurrences of LENT/SOM grade $2 objective bleeding
were reported by patients in the standard arm who had not
Table 3. Cumulative incidence and risk of proctitis
Cumulative incidence at 5 years
64 Gy 74 Gy
Symptom: scale HR 95% CI n patients % of patients n patients % of patients
Proctitis: RTOG
Grade $1 1.24 1.02–1.52 167 42 199 50
Grade $2 1.64 1.20–2.25 58 15 96 25
Grade $3 1.74 0.97–3.10 17 4 29 7
Subjective tenesmus: LENT/SOM
Grade $2 1.28 0.90–1.83 51 13 68 17
Grade $3 1.75 0.90–3.38 14 4 23 6
Grade $4 NA NA 0 0 1 0
Subjective mucosal loss: LENT/SOM
Grade $2 1.31 0.78–2.21 24 6 31 8
Grade $3 2.81 1.18–6.68 6 2 18 5
Grade $4 NA NA 0 0 1 0
Subjective sphincter control: LENT/SOM
Grade $2 2.42 1.19–4.89 10 5 25 7
Grade $3 9.25 1.17–73.02 1 0 9 2
Grade $4 NA NA 0 0 1 0
Subjective rectal pain: LENT/SOM
Grade $2 1.46 0.84–2.52 21 5 31 8
Grade $3 7.14 0.88–58.01 1 0 7 2
Grade $4 NA NA 0 0 0 0
Management sphincter control: LENT/SOM
Grade $2 3.04 0.82–11.22 3 1 9 2
Grade $3 2.54 0.49–13.07 2 0 5 1
Grade $4 NA NA 0 0 0 0
Management pelvic pain: LENT/SOM
Grade $2 3.76 1.05–13.47 3 1 11 3
Grade $3 3.07 0.32–29.53 1 0 3 1
Grade $4 NA NA 0 0 1 0
Rectal urgency: UCLA-PCI
Mild 1.06 0.88–1.27 119 57 231 61
Moderate 1.11 0.86–1.42 114 32 125 34
Severe 1.64 1.11–2.42 41 11 66 19
778 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 3, 2010previously reported this symptom (compared to 83 reports in
total over 5 years) and 35 occurrences were reported in the
escalated arm (compared to 121 over 5 years). The preva-
lence of bleeding decreased from year 3 to year 5.
Diarrhea and frequency
Incidence of diarrhea or loose stools was low preradio-
therapy according to physician-reported scores, with 38/
702 (5%) patients reporting mild symptoms and 4/702
(1%) patients reporting moderate symptoms on the
RMH questionnaire. Patients reported higher levels of
problems. Mild diarrhea was frequently reported in both
treatment arms throughout the observation period, both
before and after radiotherapy, with 341, 16, and 6 of
702 (49%, 2%, 1%, respectively) patients reporting
mild, moderate, and severe loose stools, respectively on
the UCLA-PCI preradiotherapy questionnaire; the corre-
sponding numbers for abdominal cramps on the same
questionnaire were 122 (18%), 38 (5%), and 17 (2%) of
702 patients, respectively.
Moderate-to-severe diarrhea was more commonly
reported by physicians in the escalated arm, and this differ-
ence was statistically significant for several items in thiscategory (Table 2), in particular, RTOG grade $2 (HR =
1.59; 95% CI, 1.07-2.35) and grade $3 (HR = 3.04;
95% CI, 1.21-7.67). However, grade $3 diarrhea was not
common, with only 5 standard and 16 escalated arm
patients reporting such severe symptoms by 5 years.
Once more, escalated patients required more medical
interventions according to LENT/SOM management of te-
nesmus/stool frequency, but the difference was not signifi-
cant: the cumulative incidence by 5 years of receiving
medication more than twice-weekly to control diarrhea
was 6% (n = 23 patients) for standard and 8% (n = 32 pa-
tients) for escalated patients, while 4 and 9 patients, respec-
tively, had needed multiple drugs daily. No patients
reported surgical procedures for diarrhea. Physician-
reported prevalence of diarrheal symptoms lessened once
patients reached about 3 years from radiotherapy, although
this was less clear for patient-reported outcomes. At most
time points, prevalence was higher in the escalated arm
than in the standard arm (Fig. 2).
Proctitis
Physician-reported proctitis symptoms were rare at base-
line, the most common being subjective pain (LENT/
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Fig. 3. Prevalence and cumulative incidence of proctitis. (A, B) RTOG; (C, D) rectal urgency, UCLA-PCI. Std = standard
arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
Late bowel toxicity of prostate CFRT d I. SYNDIKUS et al. 779SOM); mild symptoms were recorded for 6/702 (1%)
patients. Patients reported problems more frequently than
doctors, with 76/702 (11%) patients reporting mild rectal
urgency at preradiotherapy on UCLA-PCI, 34/702 (5%)
patients reporting moderate rectal urgency, and 12/702
(2%) patients reporting severe rectal urgency. On the
RTOG scale, mild-to-moderate proctitis was a frequent event
during follow-up; significantly more escalated than standard
arm patients reported grade $2 symptoms during follow-up
(HR = 1.64; 95% CI, 1.02-1.52) (Table 3). According to the
LENT/SOM subjective scale, cumulative incidence of grade
$2 tenesmus by 5 years was 13% (51 patients) for the stan-
dard arm and 17% (68 patients) for the escalated arm (HR =
1.28; 95% CI, 0.90-1.83). The other LENT/SOM proctitis
symptoms were also more frequently reported in the escalated
arm at all severities; this difference was statistically signifi-
cant for grade $3 mucosal loss (HR = 2.81; 95% CI, 1.18-
6.68) and grade $2 sphincter control (HR = 2.42; 95% CI,
1.19-4.89). For pelvic pain (LENT/SOM management of
pain), by 5 years, 3 standard and 11 escalated patientsrequired at least regular administration of nonnarcotic analge-
sics; and 1 standard and 3 escalated patients required regular
administration of narcotic analgesics. Medical intervention
for mucous discharge and fecal incontinence was rare
(LENT/SOM management of sphincter control); in total, by
5 years, 3 standard and 9 escalated patients used pads at least
intermittently; 2 and 5 patients, respectively, needed regular
pads. There was no significant difference between the treat-
ment arms in terms of mild or moderate rectal urgency
(UCLA-PCI) (Fig. 3); however, escalated patients were sig-
nificantly more likely to report severe symptoms (HR =
1.64; 95% CI, 1.11-2.42).
Serious bowel injury
Severe side effects associated with older radiotherapy pro-
tocols (bowel obstruction, stricture, ulceration) were rarely re-
ported in MRC RT01. Cumulative incidence of rectal ulcers
by 5 years was 1% (n = 5 patients) in the standard arm and
4% (n = 14 patients) in the escalated arm; for rectal stricture,
the corresponding proportions were 3% (n = 11 patients) and
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Fig. 4. Prevalence and cumulative incidence of patient distress and difficulties. (A, B) Bowel distress, UCLA-PCI; (C, D)
problems with bowel habits, UCLA-PCI; (E, F) trouble moving bowels, FACT-P. Std = standard arm; Esc = escalated arm;
m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
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Table 4. Cumulative incidence of difficulties with bowel habits from patient questionnaires
Cumulative incidence at 5 years
64 Gy 74 Gy
Symptom: scale HR 95% CI n patients % of patients n patients % of patients
Bowel distress: UCLA-PCI
Mild 1.08 0.91–1.29 258 68 268 61
Moderate 1.26 0.96–1.64 101 29 119 32
Severe 1.07 0.53–2.17 15 4 16 5
Bowel problems: UCLA-PCI
Mild 1.09 0.89–1.35 167 46 175 46
Moderate 1.21 0.92–1.59 96 26 110 29
Severe 1.49 0.83–2.67 19 6 28 8
Trouble moving bowel: FACT-P
Mild 1.01 0.83–1.22 211 57 210 56
Moderate 1.39 0.94–2.05 42 12 59 17
Severe 1.63 0.91–2.94 17 5 29 9
Late bowel toxicity of prostate CFRT d I. SYNDIKUS et al. 7812% (n = 8 patients), respectively. Just 7 standard and 3 esca-
lated patients had reported bowel obstruction by 5 years.Patient-reported bowel distress
Preradiotherapy, 109/702 (16%) patients reported mild, 33
(5%) patients reported moderate, and 2 (<1%) patients reported
severe distress associated with bowel movements, on the
UCLA-PCI questionnaire. Generally, the prevalence of dis-
tressing bowel movements and problem bowel habits
(UCLA-PCI) at any level increased until 2 or 3 years from start-
ing radiotherapy and then lessened; however, levels were gen-
erally still higher than baseline at 5 years in both arms (Fig. 4).
By 5 years, the cumulative incidence was 4% (15 patients) in
the standard and 5% (16) in the escalated arm for severe dis-
tressing bowel movements and 6% (19) and 8% (28) for severe
problems with bowel habits (Table 4). There were noTable 5. Cumulative incidence of late RTOG g
Toxicity
M. D.
Anderson (1) NKI (2, 3)
RT dose Gy 70 vs. 78 68 vs. 78
Setting US The Netherlands
Sites Single site Multisite
RT technique CFRT photon CFRT photon
CFRT boost CFRT boost
No. of patients
randomized
301 669
Toxicity scale RTOG-LENT
modified*
RTOG/EORTC
Median follow-up
(years)
8.7 5.8
Grade $2 64 Gy
vs. 74 Gy
13% vs. 26%
(p = 0.013)
25% vs. 35%
(p = 0.04)
Analysis time
point and type
By 10 years cumulative By 7 years cumulative
* Composite score including rectal bleeding.statistically significant differences between the arms for these
variables, but for all grades, the HR favored the standard arm.DISCUSSION
After patients received dose-escalated CFRT for prostate
cancer, we found a higher incidence and prevalence of late
bowel side effects in the dose-escalated arm after 5 years’
follow-up. Rectal bleeding, as measured using the RMH
and LENT/SOM objective bleeding scales, peaked at 24
to 36 months after radiotherapy; it then decreased by 5
years on both scales but remained higher than at pretreat-
ment. Regarding the assessment of loose stools and bowel
frequency, the RTOG, RMH, and LENT/SOM physician-
based scales showed peak late reactions occurring at 12
to 18 months, after which levels returned to near pretreat-
ment levels for the standard arm, with a slight excess forrade $2 toxicity in five randomized trials
Trial (ref.[s])
PROG
9509 (4)
RMH
pilot (5)
MRC
RT01 (6, 7)
70.2 vs 79.2 64 vs. 74 64 vs. 74
US UK UK, Australia,
New Zealand
Single site Single site Multisite
CFRT photon CFRT photon CFRT photon
Proton boost CFRT boost CFRT boost
393 126 843
RTOG RTOG original RTOG original
5.5 6.2 5.3
9% vs. 18%
(p = 0.005)
11% vs. 23%
(p = 0.02)
24% vs. 33%
(p = 0.005)
‘‘Late’’ snapshot By 2 years cumulative By 5 years cumulative
782 I. J. Radiation Oncology d Biology d Physics Volume 77, Number 3, 2010the escalated arm. It is particularly noteworthy that the
UCLA-PCI loose stool scale, showing the same general
pattern, demonstrates the prevalence and importance of re-
cording baseline bowel disturbance. RTOG proctitis
showed a peak at 18 to 36 months and then fell back to pre-
treatment levels; a similar pattern is seen with UCLA-PCI
rectal urgency, with 5-year scores being similar to those
at pretreatment. Although many of the scales showed a re-
turn to near baseline levels by 5 years, the UCLA bowel
distress and problem bowel habit items were still in excess
of pretreatment values by 5 years, after peaking at 12
months. The FACT-P ‘‘trouble with moving bowels’’ scale
seemed insensitive to treatment effects. More detailed anal-
ysis of the interrelationship and correlations between the
different scoring schemes will be presented in a future pub-
lication.
Like other trials, severe late side effects were very rare
(<1%) overall but did occur. Severe rectal bleeding,
tenesmus, and rectal ulceration were more common in the
dose-escalated group. By 5 years, 4% of standard and 5%
of escalated arm patients had reported severe distress at
some time because of altered bowel habits.
In this trial, we trained clinicians at different centers to
use the same outlining techniques, and we used standard-
ized planning techniques and employed a quality assurance
program to minimize differences between treatment centers
(6, 7). However, at planning, we did not limit the dose to
the rectum, anal canal, or small bowel in either treatment
arm; anatomical differences might therefore also contribute
to normal tissue toxicity (14–18). We used portal imaging
of pelvic bones but not other image-guided techniques;
changes in prostate position and rectal volume during
treatment were also likely to influence dose to normal tis-
sues and toxicity (19–21). We used three clinician scoring
systems (5, 10, 11) and two patient quality of life question-
naires (12, 13). Compliance from clinicians and patients
was generally good. Here, we used data only where all as-
sessments were completed for a certain time point, so the
data quality is high. As demonstrated, the scoring systems
give different details and slightly different toxicity levels.
We had to adjust the LENT/SOM scale downward for
most bowel questions (but not diarrhea) to allow compari-
son with original RTOG and RMH scales. For future trials,further efforts to standardize reporting of late side effects
are required (22–26).
Allowing for the differences in radiation dose, treatment
techniques, toxicity scales, and follow-up time, our results
are comparable with results of four published, randomized
dose escalation trials (Table 5) (1, 2, 4, 5). Across these
trials, the increase in RTOG grade $2 toxicity varied,
perhaps reflecting differences in dose increments between
the standard and escalated schedules (8 Gy and 10 Gy),
planning techniques which included initial conventional
planning (1), full conformal therapy throughout (2, 5) or
proton beam boost (4), toxicity scales, and reporting time
points. Although each trial demonstrated improvements in
biochemical control, patients with prostate cancer may
rate quality of life and freedom from troublesome side
effects as important as cancer control, and a significant
proportion might choose lower radiation doses because
of the worries of late side effects (27, 28). These results
should encourage clinicians to discuss with patients the bal-
ance of expected benefits and risks of treatment. Future re-
search might usefully assess the contribution of improved
dose distributions and normal tissue sparing using inten-
sity-modulated radiation therapy and image guidance to re-
duce treatment margins (29), the application of appropriate
dose constraints (30), and perhaps focal radiation boosts
(31) with the aim of maintaining the benefits of disease
control with dose escalation while reducing late side effects
of treatment.CONCLUSIONS
Dose-escalated radiotherapy is associated with a statisti-
cally significant increased risk of rectal bleeding, which
decreases over time. The cumulative incidence by 5 years
for moderate-or-worse bleeding was higher in the esca-
lated-dose arm. Diarrhea and proctitis were less common
than bleeding. Worrying historical side effects (obstruction,
ulceration, and fistulas) were very rare. Patient-reported
bowel distress occurred uncommonly, and many toxicities
reported seemed not to greatly trouble patients. Additional
improvements in radiotherapy technique might maintain
the benefits of dose escalation yet further improve patient
acceptability.REFERENCES1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the
M.D. Anderson randomized dose-escalation trial for prostate
cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
2. Peeters STH, Heemsbergen WD, Koper PC, et al. Dose
response in radiotherapy for localized prostate cancer: Results
of the Dutch multicenter phase III randomized trial comparing
68 Gy with 78 Gy. J Clin Oncol 2006;24: 1990–1906.
3. Al-Mamgani A, Van Putten WLJ, Heemsbergen WD, et al. Up-
date of Dutch multicenter dose-escalation trial of radiotherapy
for localized prostate cancer. Int J Radiat Oncol Biol Phys
2008;72:980–988.4. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of con-
ventional-dose versus high-dose conformal radiation therapy in
clinically localized adenocarcinoma of the prostate. JAMA
2005;294:1233–1239.
5. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study
of dose escalation using conformal radiotherapy in prostate
cancer: PSA control and side effects. Br J Cancer 2005;92:
488–498.
6. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity
of escalated versus standard dose conformal radiotherapy with
neo-adjuvant androgen suppression for patients with localized
Late bowel toxicity of prostate CFRT d I. SYNDIKUS et al. 783prostate cancer: Results from the MRC RT01 trial
(ISRCTN47772397). Radiother Oncol 2007;83:31–41.
7. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose
versus standard-dose conformal radiotherapy in prostate cancer:
First results from the MRC RT01 randomised controlled trial.
Lancet Oncol 2007;8:475–487.
8. Sydes MR, Stephens R, Moore A, et al. Implementing the
UK Medical Research Council (MRC) RT01 trial (ISRCTN
47772397): Methods and practicalities of a randomised con-
trolled trial of conformal radiotherapy in men with localised
prostate cancer. Radiother Oncol 2004;72:199–211.
9. Brenner H, Arndt V. Long-term survival rates of patients with
prostate cancer in the prostate-specific antigen screening era:
Population-based estimates for the year 2000 by period analysis.
J Clin Oncol 2005;23:441–447.
10. Pilepich MV, Asbell SO, Krall JM, et al. Correlation of radio-
therapeutic parameters and treatment related morbidity–analy-
sis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 1987;
13:1007–1012.
11. LENT SOMA tables. Radiother Oncol 1995;35:17–60.
12. Litwin MS, Hays RD, Fink A, et al. The UCLA prostate cancer
index: Development, reliability, and validity of a health-related
quality of life measure. Med Care 1998;36:1002–1012.
13. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men
with prostate cancer using the functional assessment of cancer
therapy-prostate instrument. Urology 1997;50:920–928.
14. Koper PC, Heemsbergen WD, Hoogeman MS, et al. Impact of
volume and location of the irradiated rectum wall on rectal
blood loss after radiotherapy of prostate cancer. Int J Radiat
Oncol Biol Phys 2004;58:1072–1082.
15. Michalski JM, Winter K, Purdy JA, et al. Toxicity after
three–dimensional radiotherapy for prostate cancer on
RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys
2005;62:706–713.
16. Geinitz H, Zimmerman FB, Thamm R, et al. Late rectal symp-
toms and quality of life after conformal radiation therapy for
prostate cancer. Radiother Oncol 2006;79:341–347.
17. Chan LW, Ping X, Gottschalk AR, et al. Proposed rectal dose
constraints for patients undergoing definite whole pelvic radio-
therapy for clinically localized prostate cancer. Int J Radiat
Oncol Biol Phys 2008;72:69–77.
18. Heemsbergen WD, Hoogeman MS, Hart GA, et al. Gastrointes-
tinal toxicity and its relation to dose distributions in the anorec-
tal region of prostate cancer patients treated with radiotherapy.
Int J Radiat Oncol Biol Phys 2005;61:1011–1018.
19. DeCrevoisieur R, Tucker S, Dong L, et al. Increased risk of bio-
chemical and local failure in patients with distended rectum on
the CT planning for prostate radiotherapy. Int J Radiat Oncol
Biol Phys 2005;62:965–973.20. Heemsbergen WD, Hoogeman MS, Witte MG, et al. Increased
risk of biochemical and clinical failure for prostate patients with
a large rectum at radiotherapy planning: Results from the Dutch
trial of 68 Gy versus 78 Gy. Int J Radiat Oncol Biol Phys 2007;
67:1418–1423.
21. Skala M, Rosewall T, Dawson L, et al. Patient-assessed late tox-
icity rates and principal component analysis after image-guided
radiation therapy for prostate cancer. Int J Radiat Oncol Biol
Phys 2007;68:690–698.
22. Van Der Laan HP, Van Den Bergh A, Schilstra C, et al. Grad-
ing-system-dependent volume effects for late radiation-induced
rectal toxicity after curative radiotherapy for prostate cancer. Int
J Radiat Oncol Biol Phys 2008;70:1138–1145.
23. Andreyev HJ, Vlavianos P, Blake P, Dearnaley D. Gastroin-
testinal symptoms after pelvic radiotherapy: Role for the
gastroenterologist. Int J Radiat Oncol Biol Phys 2005;62:
1464–1471.
24. Henderson A, Andreyev HJN, Stephens R, Dearnaley D. Patient
and physician reporting of symptoms and health-related quality
of life in trials of treatment for early prostate cancer: Consider-
ation for future studies. Clin Oncol 2006;18:735–743.
25. Hanlon A, Schultheiss TE, Hunt MA, et al. Chronic rectal
bleeding after high-dose conformal treatment of prostate cancer
warrants modification of existing morbidity scales. Int J Radiat
Oncol Biol Phys 1997;38:59–63.
26. Livsey JE, Routledge J, Burns M, et al. Scoring of treatment-
related late effects in prostate cancer. Radiother Oncol 2002;
65:109–121.
27. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and
satisfaction with outcome among prostate-cancer survivors.
N Engl J Med 2008;358;1250–1261.
28. Tol-Geerdink JJ, Leer JW, van Lin EN, et al. Offering a treat-
ment choice in the irradiation of prostate cancer leads to better
informed and more active patients, without harm to well-being.
Int J Radiat Oncol Biol Phys 2008;70:42–48.
29. McNair HA, Hansen VN, Parker CC, et al. A comparison of the
use of bony anatomy and internal markers for offline verifica-
tion and an evaluation of the potential benefit of online and off-
line verification protocols for prostate radiotherapy. Int J Radiat
Oncol Biol Phys 2008;71:41–50.
30. Gulliford SL, Foo K, Morgan RC, et al. Dose-volume
constraints to reduce rectal side effects from prostate
radiotherapy: Evidence from the MRC RT01 trial ISRCTN
47772397. Int J Radiat Oncol Biol Phys 2009. In press.
31. Fonteyne V, Villeirs G, Speleers B, et al. Intensity-modulated
radiotherapy as primary therapy for prostate cancer: report on
acute toxicity after dose escalation with simultaneous integrated
boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008;
72:799–807.
